NEJM This Week — June 4, 2026
A landmark trial reveals that left atrial appendage closure is non-inferior to oral anticoagulants for stroke prevention in patients with atrial fibrillation who are eligible for anticoagulation—yet it's not a clear win. The study shows the device significantly reduces bleeding risk, but experts question why a costly, invasive alternative would be considered when NOACs have a proven, decades-long safety record. The real breakthrough may not be clinical efficacy, but patient preference: shared decision-making, especially when financial incentives could bias discussions, must be protected. Meanwhile, a major trial on high-flow oxygen for respiratory failure delivers a sobering message: it doesn’t reduce mortality in unselected patients, recalibrating expectations and reminding clinicians that improving care isn’t always about extending life—but about refining the patient journey. In oncology, a promising all-oral regimen for elderly AML patients offers a major quality-of-life win, while a bold CAR-T therapy breakthrough enables kidney transplants in highly sensitized recipients. But the podcast also confronts darker truths: a gene therapy case linked to a neuroepithelial tumor raises safety alarms, and a searing perspective on corporate medicine calls out the 'perversion' of healthcare when profit eclipses healing.
Left atrial appendage closure is non-inferior to NOACs for stroke prevention in eligible AFib patients but reduces bleeding risk—making it a viable option for those prioritizing safety over long-term anticoagulation.
High-flow oxygen therapy does not reduce 28-day mortality in unselected patients with hypoxemic respiratory failure, challenging its routine use and calling for more targeted, patient-centered application.
An all-oral regimen of decitabine/cetazuridine plus venetoclax achieves nearly 50% complete response in elderly AML patients, offering a major advance in accessibility and quality of life.
Dual CAR-T cell therapy successfully enabled kidney transplants in two highly sensitized patients, opening a new frontier for overcoming HLA antibody barriers.
A neuroepithelial tumor developed four years after AAV gene therapy in a child with MPS1, with AAV vector integration into the PLAG1 gene—highlighting rare but serious oncogenic risks in gene therapy.
…and 3 more takeaways available in PodZeus
Welcome and Clinical Vignette
Dr. Lisa Johnson introduces the episode, highlighting key topics including left atrial appendage closure, oxygen strategies, AML treatment, CAR-T therapy, and gene therapy complications. She invites listeners to participate in a clinical decision-making exercise about residency interview formats.
Left Atrial Appendage Closure vs. Anticoagulation
“Given the long track record and robust evidence supporting the efficacy and safety of NOACs, why would an alternative that is only just as good even be entertained?”
High-Flow Oxygen in Respiratory Failure
“The use of high-flow oxygen should not be viewed as a mortality-reducing therapy in unselected patients with hypoxemic respiratory failure. Rather, it is a strategy that may meaningfully influence the pathway of respiratory support.”
All-Oral AML Treatment and CAR-T for Transplantation
“All oral decitabine cetazuridine plus venetoclax caused no reported drug interactions and resulted in a complete response in nearly half the patients, though with myelosuppressive effects.”
Gene Therapy Complication and Medical Ethics
“Analysis of the tumor tissue showed the integration of rearranged AAV vector elements in the gene PLAG1.”
“Starvation isn't an inevitable consequence of war, but without humanitarian access to therapeutic food, children who could be treated will die.”
“Analysis of the tumor tissue showed the integration of rearranged AAV vector elements in the gene PLAG1.”
“Aronson hears, we are playing to win in our current medical system rather than innovating to improve it.”
Host
University of California, San Francisco
organization
Sheffal Doshi
person
Vijay Bhoj
person
Jean-Pierre Fra
person
Ari Serpa Neto
person
Gail Robos
person
Gregory Marcus
person
Rebecca Ahrens-Nicholas
person
Sean O'Leary
person
Dr. Lisa Johnson
person
Start discovering podcast insights today
Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.
No credit card required • 7-day trial • Cancel anytime